RT Journal Article
SR Electronic
A1 Coltrera, Francesca
T1 ESTERN
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 8
SP 10
OP 10
DO 10.1177/1559897715588305
UL http://mdc.sagepub.com/content/15/8/10.abstract
AB In this small phase 2 study, 60% of patients with stage IIIA non–small cell lung cancer with known EGFR mutations (exon 19 or exon 21) were able to proceed to radical resection. The ultimate long-term outcomes associated with this strategy are still undetermined.